Marshall Wace, LLP Myriad Genetics Inc Transaction History

Marshall Wace, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.59 - $23.59 $590,267 - $791,609	33,557 New	33,557 $715,000
Q4 2022 Feb 14, 2023	BUY	$14.51 - $20.99 $2.13 Million - $3.09 Million	147,004 New	147,004 $2.13 Million
Q2 2022 Aug 15, 2022	SELL	$16.45 - $25.88 $1.5 Million - $2.36 Million	-91,025 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$22.67 - $28.01 $2.06 Million - $2.55 Million	91,025 New	91,025 $2.3 Million
Q4 2020 Feb 16, 2021	SELL	$12.16 - $19.77 $953,842 - $1.55 Million	-78,441 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$11.25 - $14.75 $1.68 Million - $2.2 Million	-149,211 Reduced 65.54%	78,441 $1.02 Million
Q2 2020 Aug 13, 2020	BUY	$10.69 - $16.49 $2.43 Million - $3.75 Million	227,652 New	227,652 $2.58 Million
Q3 2019 Nov 14, 2019	SELL	$22.08 - $47.08 $3.44 Million - $7.34 Million	-155,916 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$22.67 - $35.0 $3.53 Million - $5.46 Million	155,916 New	155,916 $4.33 Million
Q1 2019 May 14, 2019	SELL	$26.93 - $34.7 $9.06 Million - $11.7 Million	-336,435 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$27.23 - $45.56 $9.16 Million - $15.3 Million	336,435 New	336,435 $9.78 Million

233

92.6M

117K

113K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $2.13B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.